APEPTICO - Innovation in peptide drugs
SOLNATIDE: Read the most exciting news related to the exploration of safety, tolerability and clinical efficacy of SOLNATIDE IMP in patients infected with the 2019 new Coronavirus (SARS-CoV-2)
After preparing the Horizon 2020 Grant and Consortium Agreements in record time due to the urgent situation caused by the Corona pandemic, we now have kicked-off the SOLNATIDE project.
The Scientific Coordinator and initiator of the project Prof. Dr. Bernhard Fischer is CEO of the Viennese biotechnology company APEPTICO Forschung und Entwicklung GmbH which is proprietary owner of the medicinal product Solnatide IMP.
As coordinator, RTDS is responsible for the overall project coordination, as well as project management and communication.
The SOLNATIDE project in a nutshell
Funding: €1.626 million
Funding: European Commission (EC) call “H2020-SC1-PHE-CORONAVIRUS-2020” (grant no. 101003595)
Project start: April 1st 2020
Duration: 21 months
Consortium: 5 partners from Austria, Germany, Italy and Spain (in alphabetic order)
- APEPTICO Forschung und Entwicklung GmbH, Austria. Scientific coordinator.
- BCN Peptides SA, Spain.
- Ludwig-Maximilians-University Munich (LMU) University Hospital, Germany.
- OPIS SRL, Italy.
- RTDS Association, Austria. RTDS Association is responsible for the overall project coordination, as well as project management and communication.
This project has received funding from the EC special H2020 program “Advancing knowledge for the clinical and public health response to the 2019-nCoV epidemic (call )) under the grant no. 101003595.